Theravance Biopharma, Inc.

NasdaqGM:TBPH Stock Report

Market Cap: US$421.9m

Theravance Biopharma Future Growth

Future criteria checks 5/6

Theravance Biopharma is forecast to grow earnings and revenue by 56.8% and 23.3% per annum respectively while EPS is expected to grow by 55.9% per annum.

Key information

56.8%

Earnings growth rate

55.9%

EPS growth rate

Pharmaceuticals earnings growth21.4%
Revenue growth rate23.3%
Future return on equityn/a
Analyst coverage

Low

Last updated05 Mar 2024

Recent future growth updates

Recent updates

Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Feb 05
Some Confidence Is Lacking In Theravance Biopharma, Inc.'s (NASDAQ:TBPH) P/S

Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Nov 11
Upgrade: Analysts Just Made A Sizeable Increase To Their Theravance Biopharma, Inc. (NASDAQ:TBPH) Forecasts

Theravance to purchase $95M of ordinary shares

Sep 28

Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Sep 21
Things Look Grim For Theravance Biopharma, Inc. (NASDAQ:TBPH) After Today's Downgrade

Theravance Biopharma announces $250M capital return program

Sep 19

Theravance Biopharma GAAP EPS of -$0.11, revenue of $11.1M

Aug 04

Theravance: All-Round Failure

Mar 10

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Aug 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Just Trimmed Their Revenue Forecasts By 27%

Theravance Bio stock falls 6% after nezulcitinib flunks mid-stage COVID-19 induced lung injury study

Jun 21

Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

May 09
Theravance Biopharma, Inc. (NASDAQ:TBPH) Analysts Are Reducing Their Forecasts For This Year

Theravance Biopharma EPS misses by $0.16, misses on revenue

May 04

Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Apr 21
Shareholders May Not Be So Generous With Theravance Biopharma, Inc.'s (NASDAQ:TBPH) CEO Compensation And Here's Why

Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Mar 13
Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)

Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Mar 08
Is Theravance Biopharma, Inc. (NASDAQ:TBPH) Expensive For A Reason? A Look At Its Intrinsic Value

Earnings and Revenue Growth Forecasts

NasdaqGM:TBPH - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202613965110N/A4
12/31/202597-167N/A4
12/31/202473-32-13N/A4
12/31/202357-55-29-27N/A
9/30/202355-61-152-150N/A
6/30/202351-68-172-170N/A
3/31/202349-75-173-172N/A
12/31/202251-93-188-187N/A
9/30/202252-136-106-105N/A
6/30/202252-196-131-129N/A
3/31/202254-226-166-164N/A
12/31/202155-265-211-208N/A
9/30/202159-266-235-230N/A
6/30/202164-264-267-262N/A
3/31/202166-275-273-265N/A
12/31/202072-295-257-250N/A
9/30/202083-285-257-250N/A
6/30/202077-270-222-217N/A
3/31/202088-247-215-212N/A
12/31/201973-236-241-238N/A
9/30/201960-221-229-226N/A
6/30/201960-222-236-230N/A
3/31/201957-223-250-244N/A
12/31/201860-216-120-113N/A
9/30/201849-252-111-105N/A
6/30/201841-260-123-118N/A
3/31/201821-285-106-101N/A
12/31/201715-285-203-201N/A
9/30/201717-266N/A-185N/A
6/30/201731-233N/A-135N/A
3/31/201733-214N/A-123N/A
12/31/201649-191N/A-99N/A
9/30/201647-168N/A-105N/A
6/30/201638-182N/A-124N/A
3/31/201640-182N/A-139N/A
12/31/201542-182N/A-169N/A
9/30/201540-202N/A-178N/A
6/30/201535-209N/A-182N/A
3/31/201531-219N/A-187N/A
12/31/201412-237N/A-175N/A
9/30/201410-217N/A-168N/A
6/30/20144-203N/A-164N/A
3/31/20141-184N/A-137N/A
12/31/20130-156N/A-121N/A
9/30/20135-141N/A-108N/A
6/30/20135-133N/A-100N/A
3/31/20134-129N/A-109N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: TBPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: TBPH is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: TBPH is expected to become profitable in the next 3 years.

Revenue vs Market: TBPH's revenue (23.3% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: TBPH's revenue (23.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TBPH's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.